NICE Technology Appraisal Guidance No 113 - Inhaled Insulin for
the Treatment of Diabetes (Types 1 and 2)
In January 2008, Pfizer ceased production of its inhaled
insulin product Exubera. NICE technology appraisal 113 on inhaled
insulin for diabetes (types I and II) has therefore been made
obsolete and the corresponding NHS QIS advice withdrawn.
Published Date: 24 January 2007
